Objective:

To examine cell-based therapies and extracellular vesicles (EVs) as adjunctive regenerative strategies for acute kidney injury (AKI) in critically ill patients.

Approach:

• Regenerative Options: Discusses the need for regenerative therapies in AKI management due to the limitations of current supportive care.
• Biological Heterogeneity: Explores the diverse biological mechanisms underlying AKI, emphasizing the importance of tailored therapeutic approaches.
• Integration with Organ Support: Analyzes how MSCs and EVs can interact with extracorporeal organ-support platforms to enhance renal recovery.

Key Findings:

• AKI affects up to 50% of ICU patients and is associated with high mortality rates.
• Current management strategies do not address the underlying biological mechanisms of AKI.
• MSCs and MSC-derived EVs show promise in reducing inflammation and promoting renal recovery in preclinical studies.
• Early clinical trials indicate safety of MSC and EV therapies in AKI populations.
• Heterogeneity in AKI etiology complicates treatment and highlights the need for phenotype-enriched patient selection.

Interpretation:

The findings suggest that while regenerative therapies like MSCs and EVs have potential, their clinical application is hindered by AKI's biological complexity and the need for better-defined therapeutic strategies.

Limitations:

• Early clinical trials have shown limited efficacy signals.
• Current biomarkers are insufficient to predict patient recovery or the need for dialysis.
• The heterogeneity of AKI complicates the identification of optimal treatment approaches.

Conclusion:

Future advancements in AKI treatment may depend on improved patient selection, biomarker-guided interventions, and the development of standardized dosing and potency assays for EV therapies.